PHARMING GROUP NV - ADR (PHAR) Forecast, Price Target & Analyst Ratings

NASDAQ:PHAR • US71716E1055

Current stock price

16.44 USD
+0.09 (+0.55%)
Last:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PHARMING GROUP NV - ADR (PHAR).

Forecast Snapshot

Consensus Price Target

Price Target
$25.84
+ 57.20% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
$0.07
Revenue Estimate
96.563M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
88.57%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$25.84
Upside
+ 57.20%
From current price of $16.44 to mean target of $25.84, Based on 14 analyst forecasts
Low
$20.82
Median
$25.99
High
$31.26

Price Target Revisions

1 Month
43.64%
3 Months
30.69%

Price Target Summary

14 Wall Street analysts provided a forecast for the next 12 months for PHAR. The average price target is 25.84 USD. This implies a price increase of 57.2% is expected in the next year compared to the current price of 16.44.
The average price target has been revised upward by 30.69% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

PHAR Current Analyst RatingPHAR Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

PHAR Historical Analyst RatingsPHAR Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
88.57%
PHAR was analyzed by 14 analysts. The buy percentage consensus is at 89. So analysts seem to be very confident about PHAR.
In the previous month the buy percentage consensus was at a similar level.
PHAR was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-10Canaccord GenuityInitiate Buy
2026-03-24HC Wainwright & Co.Reiterate Buy -> Buy
2026-03-13OppenheimerReiterate Outperform -> Outperform
2025-03-21HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-20HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-14OppenheimerMaintains Outperform -> Outperform
2025-03-14HC Wainwright & Co.Reiterate Buy -> Buy
2024-12-17HC Wainwright & Co.Reiterate Buy -> Buy
2024-12-16HC Wainwright & Co.Reiterate Buy -> Buy
2024-12-11HC Wainwright & Co.Reiterate Buy -> Buy
2024-12-09JefferiesInitiate Buy
2024-10-28OppenheimerMaintains Outperform -> Outperform
2024-10-24HC Wainwright & Co.Reiterate Buy -> Buy
2024-10-15HC Wainwright & Co.Reiterate Buy -> Buy
2024-10-10HC Wainwright & Co.Reiterate Buy -> Buy
2024-09-26HC Wainwright & Co.Reiterate Buy -> Buy
2024-08-01HC Wainwright & Co.Reiterate Buy -> Buy
2024-05-31HC Wainwright & Co.Reiterate Buy -> Buy
2024-03-14HC Wainwright & Co.Reiterate Buy -> Buy
2023-08-03HC Wainwright & Co.Reiterate Buy
2023-03-28OppenheimerMaintains Outperform
2023-03-27HC Wainwright & Co.Reiterate Buy
2023-02-22HC Wainwright & Co.Reiterate Buy
2023-02-16HC Wainwright & Co.Reiterate Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 7, 2026
Period
Q1 / 2026
EPS Estimate
$0.07
Revenue Estimate
96.563M
Revenue Q2Q
22.09%
EPS Q2Q
130.43%
Number of Analysts
5

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
0.81%
EPS (1 Month)
296.15%
EPS (3 Months)
-70.14%

Next Earnings Summary

PHAR is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is 0.07 USD and the consensus revenue estimate is 96.56M USD.
The next earnings revenue estimate has been revised upward by 0.81% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2031

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031
Revenue
YoY % growth
PHAR revenue by date.PHAR revenue by date.
245.316M
19.30%		297.2M
21.15%		376.134M
26.56%		413.89M
10.04%		424.26M
2.51%		381.56M
-10.06%		507.34M
32.96%		807.93M
59.25%		485.44M
-39.92%
EBITDA
YoY % growth
PHAR ebitda by date.PHAR ebitda by date.
-5.825M
-124.73%		12.476M
314.18%		43.972M
252.45%		25.184M
-42.73%		30.488M
21.06%		58.882M
93.13%		134.3M
128.08%		235.66M
75.47%		N/A
EBIT
YoY % growth
PHAR ebit by date.PHAR ebit by date.
-21.75M
-309.80%		-3.594M
83.48%		32.756M
1,011.41%		32.497M
-0.79%		34.68M
6.72%		36.256M
4.54%		94.194M
159.80%		145.13M
54.08%		42.453M
-70.75%
Operating Margin
PHAR operating margin by date.PHAR operating margin by date.
-8.87%-1.21%8.71%7.85%8.17%9.50%18.57%17.96%8.75%
EPS
YoY % growth
PHAR eps by date.PHAR eps by date.
-0.16
-132.92%		-0.18
-12.50%		0.02
111.11%		0.35
1,671.60%		0.45
27.91%		0.47
5.30%		1.13
137.43%		1.62
43.81%		N/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		0.07
130.43%		0.10
71.67%		0.10
-2.15%		0.09
9.44%
Revenue
Q2Q % growth		96.563M
22.09%		105.99M
13.72%		111.6M
14.70%		114.42M
7.40%
EBITDA
Q2Q % growth		6.18M
85.14%		13.287M
-27.13%		13.905M
-42.14%		14.626M
-17.04%
EBIT
Q2Q % growth		5.768M
662.96%		9.167M
-29.21%		11.33M
-29.29%		9.888M
54.16%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

PHAR Yearly Revenue VS EstimatesPHAR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
PHAR Yearly EPS VS EstimatesPHAR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
187.89%
EPS Next 5 Year
141.10%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
0.12%
Revenue Next 5 Year
16.27%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
34.62%
EBIT Next 5 Year
57.73%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

PHARMING GROUP NV - ADR / PHAR Forecast FAQ

What do analysts expect the price target to be for PHARMING GROUP NV - ADR (PHAR)?

14 analysts have analysed PHAR and the average price target is 25.84 USD. This implies a price increase of 57.2% is expected in the next year compared to the current price of 16.44.

Can you provide the upcoming earnings date for PHARMING GROUP NV - ADR?

PHARMING GROUP NV - ADR (PHAR) will report earnings on 2026-05-07.

What are the consensus estimates for PHAR stock next earnings?

The consensus EPS estimate for the next earnings of PHARMING GROUP NV - ADR (PHAR) is 0.07 USD and the consensus revenue estimate is 96.56M USD.

What is the number of analysts for PHAR stock?

The number of analysts covering PHARMING GROUP NV - ADR (PHAR) is 14.